Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2020

Open Access 01.12.2020 | Research article

Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study

verfasst von: Yi Yang, Yanan Xu, Jun Wang, Xueqin Zhai, Haibing Jiang

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2020

Abstract

Background

Inflammation is involved in the pathogenesis and progression of coronary artery diseases (CADs), including acute coronary syndrome. The neutrophil-to-lymphocyte ratio (NLR) has been identified as a novel marker of the pro-inflammatory state. We aimed to evaluate the predictive efficacy of the NLR for the prognosis of patients with new-onset ACS.

Methods

We retrospectively included consecutive patients with new-onset ACS treated with emergency coronary angiography. NLR was measured at baseline and analyzed by tertiles. The severity of coronary lesions was evaluated by the Gensini score. Correlations of NLR with the severity of CAD and the incidence of major adverse cardiovascular diseases (MACEs) during follow-up were determined.

Results

Overall, 737 patients were included. The NLR was positively correlated with the severity of coronary lesions as assessed by Gensini score (P < 0.05). During the follow-up period (mean, 43.49 ± 23.97 months), 65 MACEs occurred. No significant association was detected between baseline NLR and the risk of MACEs during follow-up by either Kaplan–Meier or Cox regression analysis. Multivariable logistic regression analysis showed that a higher NLR was independently associated with coronary lesion severity as measured by the Gensini score (1st tertile vs. 3rd tertile hazard ratio [HR]: 0.527, P < 0.001, and 2nd tertile vs. 3rd tertile HR: 0.474, P = 0.025).

Conclusions

The NLR may be associated with coronary disease severity at baseline but is not associated with adverse outcomes in patients with new-onset ACS.

Ethics Approval Number

2019XE0208
Hinweise
Yi Yang, Yanan Xu and Jun Wang these authors contributed to the work equally and should be regarded as co-first authors

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BMI
Body mass index;
SBP
Systolic blood pressure
DBP
Diastolic blood pressure
NLR
Neutrophil to lymphocyte ratio
WBC
White blood count
PLT
Platelet count
MPV
Mean platelet volume
PCT
Thrombocytocrit
PDW
Platelet distribution width
RBC
Red blood cell
HGB
Hemoglobin
BUN
Blood urea nitrogen
Cr
Creatinine
TC
Total cholesterol
TG
Triglyceride
HDL-c
High-density lipoprotein cholesterol
LDL-c
Low-density lipoprotein-cholesterol
Apo-AI
Apolipoprotein A1
Apo-B
Apolipoprotein B
Lp(a)
Lipoprotein (a)
CCB
Calcium channel blocker
ACEI
Angiotensin-converting enzyme inhibitor
ARB
Angiotensin receptor blocker
CAD
Coronary artery disease
LAD
Left anterior descending artery
LCX
Left circumflex artery
RCA
Right coronary artery
UA
Unstable angina
NSTEMI
Non–ST-segment elevation myocardial infarction
STEMI
ST-segment elevation myocardial infarction
ACM
All-cause mortality
CM
Cardiac mortality
MACE
Major adverse cardiovascular events
ST
Stent thrombosis
PCI
Percutaneous transluminal coronary intervention
CI
Confidence interval
HR
Hazard ratio

Background

The current understanding of the pathogenesis of atherosclerosis is focused on the "inflammatory hypothesis of atherothrombosis" theory [1, 2]. Inflammatory cells and inflammatory signaling pathways play complex roles in the process of atherosclerosis, including initiating repair after vascular injury and mediating plaque instability and rupture, finally leading to acute coronary events [36]. Patients with acute coronary syndrome (ACS), particularly those with new-onset ACS, often have an unstable clinical status and a poor prognosis, and optimization of risk stratification is clinically important in this patient group [7, 8].
Pathological studies have confirmed an increase in white blood cell mobilization in necrotic areas of the myocardium [9]. Moreover, white blood cell count, a clinical marker of universal inflammation, was shown to be independently associated with the risk of mortality and incidence of major adverse cardiovascular events (MACEs) in ACS patients [10, 11]. However, white blood cell count is unstable and tends to be affected by comorbidities such as infection. Interesting, it has also been indicated that decreased lymphocyte numbers may be associated with acute coronary events [12]. Recent studies showed that the neutrophil-to-lymphocyte ratio (NLR), which incorporates two major subgroups of white blood cells, may confer prognostic efficacy in many diseases, including inflammatory diseases, cardiovascular diseases, and malignancies [13, 14]. It has been suggested that an elevated NLR is associated with increased long-term mortality in patients with acute myocardial infarction (AMI) complicated by left main-and/or three-vessel disease [15]. Moreover, the role of the NLR for the management of patients with coronary artery disease (CAD) has also been evaluated, and the results showed that the NLR is correlated with CAD severity [1618]. However, these studies were of limited scale and patients with a previous diagnosis of CAD were not excluded. Overall, clinical and experimental data support an important role for inflammation in CAD [1, 2].
Whether the NLR remains a significant prognostic factor after control for the severity of coronary lesions in new-onset ACS remains to be determined. Therefore, in this study, we retrospectively enrolled patients with new-onset ACS to comprehensively evaluate the potential prognostic role of the NLR in these patients.

Methods

Patients and study design

Consecutive patients with a first diagnosis of ACS who were admitted to the Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital affiliated to the Xinjiang Medical University from January 2011 to January 2019 were included. ACS was diagnosed in accordance with previously established guidelines [19]. Patients with the following clinical conditions that may affect the NLR were excluded: hepatic or renal dysfunction, malignant tumors, acute infection, connective tissue disease, physical and chemical damage, previously proven systemic inflammatory disease, and recent surgery. Moreover, patients with a previous diagnosis of CAD were also excluded. The protocol of the study was approved by the ethics committee of our local institution before enrollment of the patients. Informed patient consent was not needed due to the retrospective design of the study.

Blood sampling and definitions of CAD risk factors

Venous blood samples were taken when patients initially presented to the emergency department or prior to angiography, and the samples were sent immediately for laboratory analysis. Hypertension was defined if the patient was taking any antihypertensive medications or had blood pressure measurements over 140/90 mmHg on least two separate occasions [20]. Diabetes was diagnosed based on medical history or measurements of fasting and/or postprandial glucose according to previous guidelines [21]. The estimated glomerular filtration rate (eGFR) was calculated with the Modification of Diet in Renal Diseases equation [22].

Coronary angiography and Gensini score

All patients underwent coronary angiography within 12 h of admission. Two independent investigators assessed the degrees of stenosis of the coronary lesions. Consensus with a third investigator was indicated if disagreement occurred. The Gensini score (GS), which incorporates both the extent of luminal narrowing and the geographic importance of the lesion, was calculated to reflect the severity of coronary lesions [23]. We used the GS instead of the SYNTAX system to reflect the severity of coronary lesions, because the calculation method of SYNTAX integral is more complicated. This limits its use in clinical practice and makes it difficult to apply to emergency patients, such as those with new-onset ACS. Moreover, research has shown that the SYNTAX score cannot be utilized to define future risk as the Gensini score can in patients with non-obstructive CAD [24].

Outcomes

Patients were followed by telephone interview or clinic visit. The primary outcome was all-cause mortality. The secondary outcome was a composite of MACEs, including cardiac mortality, non-fatal myocardial infarction and stroke, stent thrombosis, and revascularization (unplanned repeat PCI).

Statistical analysis

Continuous variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR), whereas categorical variables were presented as percentages. Patients were grouped according the tertiles of the NLR or GS. One-way analysis of variance (ANOVA) was used to evaluate the difference in normally distributed numeric variables among the groups, while for the non-normally distributed variables, Mann–Whitney U test or Kruskal–Wallis variance analysis was used. For the categorical variables, a chi-square (χ2) test was employed. Linear regression analysis was performed to identify the factors associated with the GS. Prognostic factors for the occurrence of mortality and MACEs were analyzed with Kaplan–Meier survival method. Univariate analysis was first performed, and then significant variables were included in the multivariate Cox analysis. A P value < 0.05 indicated a statistically significant difference. All analyses were performed using SPSS 22.0 (SPSS Inc, Chicago, IL, USA).

Results

Characteristics of patients according to NLR

A flow chart outlining patient enrollment is shown in Fig. 1. A total of 737 patients with new on-set ACS were included. The baseline characteristics of the included patients according to the tertiles of NLR are shown in Table 1. The results showed that patients with a higher NLR were more likely to have dyslipidemia and ST-elevation myocardial infarction (STEMI; both P < 0.05).
Table 1
Baseline characteristics of the included patients according to NLR tertiles
 
1st tertile ≤ 3.37 (n = 245)
2nd tertile 3.38–6.93 (n = 245)
3rd tertile ≥ 6.94 (n = 247)
t/Z/χ2
P
Sex (male/female)
200/45
203/42
213/34
2.039
0.361
Age (years)
58.20 ± 12.46
57.20 ± 12.45
58.64 ± 12.04
0.877
0.417
Hypertension
113 (46.1)
115 (46.9)
103 (41.7)
1.582
0.453
Diabetes mellitus
76 (31.0)
64 (26.1)
53 (21.5)
5.820
0.054
DM treatment
   
3.808
0.433
 Diet only
4 (6.6)
2 (3.6)
2 (4.9)
  
 Oral hypoglycemic drugs
23 (37.7)
30 (54.5)
21 (51.2)
  
 Insulin
34 (55.7)
23 (41.8)
18 (43.9)
  
Smoking
   
9.319
0.054
 Never smoker
110 (44.9)
132 (53.9)
115 (46.6)
  
 Former smoker
19 (7.8)
7 (2.9)
11 (4.5)
  
 Current smoker
116 (47.3)
106 (43.3)
121 (49.0)
  
Alcohol drinking
   
2.390
0.664
 Never drinking
151 (61.9)
149 (61.3)
146 (59.3)
  
 Former drinking
35 (14.3)
35 (14.4)
46 (18.7)
  
 Current drinking
58 (23.8)
59 (24.3)
54 (22.0)
  
Family history of CAD
99 (40.4)
101 (41.2)
97 (39.3)
0.197
0.906
SBP (mmHg)
122.02 ± 20.97
122.91 ± 19.32
122.21 ± 19.17
0.137
0.872
DBP (mmHg)
75.96 ± 13.59
76.75 ± 12.90
77.23 ± 13.84
0.567
0.567
Heart rate (bpm)
82.78 ± 15.31
80.54 ± 14.71
82.50 ± 15.03
1.618
0.199
BMI (kg/m2)
25.11 ± 5.28
25.04 ± 5.15
24.63 ± 5.94
0.475
0.622
HDL-C (mmol/l)
0.95 ± 0.26
1.00 ± 0.26
1.01 ± 0.26
2.575
0.077
LDL-C (mmol/l)
2.93 ± 0.91
2.96 ± 0.84
2.97 ± 0.85
0.095
0.910
TC (mmol/l)
4.61 ± 1.22
4.66 ± 1.26
4.59 ± 1.08
0.181
0.834
TG (mmol/l)
1.76 ± 1.13
2.04 ± 1.06a
2.26 ± 1.17ab
11.988
 < 0.001
ApoA1 (g/L)
1.21 ± 0.29
1.28 ± 0.53
1.22 ± 0.27
1.604
0.202
ApoB (g/L)
0.92 ± 0.49
0.90 ± 0.27
0.91 ± 0.26
0.160
0.852
Lp (a) (g/L)
244.88 ± 258.72
236.56 ± 227
239.63 ± 214.2
0.059
0.942
Creatinine (mmol/L)
79.27 ± 36.5
81.75 ± 56.31
79.25 ± 35.77
0.259
0.772
BUN (mmol/l)
5.42 ± 2.76
5.69 ± 2.26
5.68 ± 2.81
0.833
0.435
Uric acid (mmol/L)
334.27 ± 90.96
326.4 ± 88.92
325.73 ± 99.45
0.629
0.534
WBC
9.03 ± 3.21
11.05 ± 3.35a
12.32 ± 3.41ab
61.212
 < 0.001
Monocyte count
0.63 ± 0.24
0.66 ± 0.34
0.46 ± 0.32ab
30.768
 < 0.001
PLR
89.94 ± 36.52
145.34 ± 110.94a
265.13 ± 175.65ab
132.705
 < 0.001
RBC
4.77 ± 0.72
4.85 ± 0.58
4.65 ± 0.82b
4.852
0.008
HGB
145.04 ± 22.16
144.99 ± 26.14
142.53 ± 28.78
0.759
0.468
PLT
224.49 ± 71.94
229.48 ± 144.24
236.26 ± 162.19
0.492
0.612
MPV
10.16 ± 1.43
10.26 ± 1.24
10.14 ± 1.66
0.499
0.608
PDW
13.36 ± 3.83
13.43 ± 3.71
13.31 ± 3.22
0.065
0.937
PCT
0.24 ± 0.08
0.23 ± 0.09
0.25 ± 0.12
1.632
0.196
Clinical diagnosis
   
20.160
 < 0.001
 UA
52 (21.2)
29 (11.8)
19 (7.7)
  
 NSTEMI
26 (10.7)
30 (12.2)
31 (12.6)
  
 STEMI
167 (68.2)
186 (75.9)
197 (79.8)
  
Coronary artery lesion
     
 UPLMT
22 (9.2)
25 (10.6)
21 (8.7)
0.526
0.769
 LAD
217 (88.9)
211 (86.5)
216 (87.8)
0.687
0.709
 LCX
155 (64.3)
147 (61.0)
155 (63.0)
0.577
0.749
 RCA
179 (74.0)
178 (73.3)
186 (75.3)
0.278
0.870
Medication situation
     
 Aspirin
20 (8.2)
32 (13.1)
22 (8.9)
3.782
0.151
 Statins
18 (7.3)
28 (11.4)
21 (8.5)
2.625
0.269
 β-Blockers
16 (6.5)
16 (6.5)
12 (4.9)
0.818
0.664
 ACEI/ARB
8 (3.3)
13 (5.3)
6 (2.4)
3.049
0.218
 CCB
41 (16.7)
26 (10.6)
35 (14.2)
3.885
0.143
aP < 0.05 compared to the 1st tertile; bP < 0.05 compared to the 2nd tertile

Incidence of mortality and MACEs according to the NLR

The incidences of clinical outcomes during follow-up (mean, 43.49 ± 23.97 months) for the included patients with new-onset ACS according to the NLR are shown in Table 2. No significant differences in the incidences of all-cause mortality, overall and components of MACEs, or bleeding events were detected among the three groups (all P ≥ 0.05).
Table 2
Incidence of adverse outcomes in ACS patients according to the NLR tertiles
 
1st tertile ≤ 3.37 (n = 245)
2nd tertile 3.38–6.93 (n = 245)
3rd tertile ≥ 6.94 (n = 247)
χ2
P
ACM, n (%)
5 (2.0)
12 (4.9)
7 (2.8)
3.385
0.184
Non-sudden cardiac death, n (%)
1 (0.4)
0 (0.0)
0 (0.0)
1.825
0.665
MACE, n (%)
21 (8.6)
24 (9.8)
20 (8.1)
0.469
0.791
 CM, n (%)
4 (1.6)
12 (4.9)
7 (2.8)
4.421
0.110
 Re-myocardial infarction, n (%)
4 (1.6)
0 (0.0)
2 (0.8)
5.578
0.061
 ST, n (%)
0 (0.0)
0 (0.0)
2 (0.8)
2.617
0.332
 Revascularization, n (%)
11 (4.5)
17 (6.9)
12 (4.9)
1.666
0.435
 Stroke, n (%)
1 (0.4)
0 (0.0)
2 (0.8)
2.764
0.251
Bleeding events, n (%)
1 (0.4)
6 (2.4)
1 (0.4)
5.904
0.052

Characteristics of patients according to GS

The baseline characteristics of patients according to the tertiles of GS (1st tertile GS < 49; n = 250, 2nd tertile GS: 49 ~ 85; n = 246, and 3rd tertile GS > 85; n = 241) are shown in Table 3. The percentage of male patients, age, prevalence of diabetes mellitus, and history of smoking differed significantly among the groups according to GS tertile (all P < 0.05). However, we found no relationship between other indicators and coronary severity (all P > 0.05).
Table 3
Baseline characteristics of the included patients according to the GS tertiles
 
1st tertile ≤ 45 (n = 250)
2nd tertile 49–85 (n = 246)
3rd tertile ≥ 85 (n = 241)
t/Z/χ2
P
Sex (male/female)
171/79
191/55
200/41
14.814
0.001
Age (years)
55.37 ± 12.26
58.23 ± 11.84a
60.53 ± 12.34ab
11.111
 < 0.001
Hypertension
106 (42.4)
111 (45.1)
114 (47.3)
1.199
0.549
Diabetes mellitus
45 (18.0)
66 (26.8)
82 (34.0)ab
16.381
 < 0.001
Diabetes mellitus treatment
   
0.846
0.932
 Diet only
2 (4.2)
3 (6.7)
3 (4.7)
  
 Oral hypoglycemic drugs
23 (47.9)
19 (42.2)
32 (50.0)
  
 Insulin
23 (47.9)
23 (51.1)
29 (45.3)
  
Smoking
   
9.963
0.041
 Never smoker
134 (53.6)
119 (48.4)
104 (43.2)
  
 Former smoker
16 (6.4)
13 (5.3)
8 (3.3)
  
 Current smoker
100 (40.0)
114 (46.3)
129 (53.5)
  
Alcohol drinking
   
1.053
0.902
 Never drinking
147 (58.8)
153 (63.2)
146 (60.6)
  
 Former drinking
41 (16.4)
36 (14.9)
39 (16.2)
  
 Current drinking
62 (24.8)
53 (21.9)
56 (23.2)
  
Family history of CAD
95 (38.0)
100 (40.7)
102 (42.3)
0.972
0.615
SBP (mmHg)
123.72 ± 20.64
122.37 ± 18.87
121 ± 19.85
1.157
0.315
DBP (mmHg)
76.86 ± 13.88
77.45 ± 13.12
75.62 ± 13.3
1.174
0.310
Heart rate
80.42 ± 14.05
81.78 ± 14.26
83.68 ± 16.58
2.930
0.054
BMI (kg/m2)
24.78 ± 5.95
24.9 ± 5.05
25.11 ± 5.36
0.203
0.817
HDL-C (mmol/l)
0.96 ± 0.23
0.99 ± 0.26
1.01 ± 0.28
2.152
0.117
LDL-C (mmol/l)
2.88 ± 0.85
2.94 ± 0.74
3.04 ± 1
1.434
0.239
TC (mmol/l)
4.63 ± 1.23
4.57 ± 0.98
4.68 ± 1.34
0.374
0.688
TG (mmol/l)
2.14 ± 2.15
2.15 ± 2.13
1.98 ± 1.45
0.426
0.653
ApoA1 (g/L)
1.2 ± 0.26
1.23 ± 0.3
1.29 ± 0.53
2.710
0.067
ApoB (g/L)
0.9 ± 0.27
0.88 ± 0.23
0.96 ± 0.52
2.433
0.089
Lp(a) (g/L)
234.48 ± 232.84
263.47 ± 280.29
222 ± 172.39
1.505
0.223
Cr (mmol/L)
80.9 ± 35.25
80.52 ± 42.9
78.84 ± 52.29
0.150
0.860
BUN (mmol/l)
5.71 ± 2.91
5.59 ± 2.87
5.5 ± 1.95
0.394
0.674
Uric acid (μmol/L)
326.22 ± 92.64
335.89 ± 94.27
324.19 ± 92.59
1.090
0.337
WBC
10.88 ± 3.74
10.87 ± 3.71
10.64 ± 3.29
0.339
0.712
Neutrophil count
8.13 ± 3.63
8.37 ± 3.58
8.11 ± 3.15
0.419
0.658
lymphocyte count
1.95 ± 1.27
1.76 ± 0.96
1.81 ± 1.07
1.954
0.142
NLR
5.24 ± 3.90
6.41 ± 5.24
7.46 ± 5.51
12.506
 < 0.001
NLR tertiles
   
19.287
0.001
 1st tertile
104 (41.6)
77 (31.3)
64 (26.6)
  
 2nd tertile
84 (33.6)
84 (34.1)
77 (32.0)
  
 3rd tertile
62 (24.8)
85 (34.6)
100 (41.5)
  
Monocyte count
0.59 ± 0.32
0.58 ± 0.32
0.57 ± 0.31
0.258
0.773
PLR
158.09 ± 122.37
176.51 ± 159.31
166.74 ± 142.57
1.042
0.353
RBC
4.75 ± 0.70
4.74 ± 0.73
4.79 ± 0.72
0.399
0.672
HGB
145.15 ± 24.97
142.77 ± 27.85
144.62 ± 24.6
0.579
0.561
PLT
223.74 ± 69.67
242.01 ± 203.23
224.52 ± 77.66
1.508
0.222
MPV
10.20 ± 1.29
10.16 ± 1.75
10.2 ± 1.28
0.065
0.937
PDW
13.66 ± 3.35
13.44 ± 3.78
12.98 ± 3.63
2.298
0.101
PCT
0.24 ± 0.08
0.24 ± 0.11
0.24 ± 0.10
0.239
0.788
Clinical diagnosis
   
1.672
0.796
 UA
38 (15.2)
32 (13.0)
30 (12.4)
  
 NSTEMI
32 (12.8)
26 (10.6)
29 (12.0)
  
 STEMI
180 (72.0)
188 (76.4)
182 (75.5)
  
 Aspirin
18 (7.2)
23 (9.3)
33 (13.7)
5.923
0.052
 Statins
17 (6.8)
19 (7.7)
31 (12.9)ab
6.029
0.043
 β-Blockers
15 (6.0)
12 (4.9)
17 (7.1)
1.027
0.598
 ACEI/ARB
7 (2.8)
8 (3.3)
12 (5.0)
1.828
0.401
 CCB
32 (12.8)
34 (13.8)
36 (14.9)
0.470
0.790
Abbreviations are as in Table 1

Factors associated with coronary lesion severity as detected by Gensini Score

The results of multivariable logistic regression analysis showed that a higher NLR was independently associated with coronary lesion severity as measured by the GS (1st tertile vs. 3rd tertile hazard ratio [HR]: 0.527, P < 0.001, and 2nd tertile vs. 3rd tertile HR: 0.474, P = 0.025). The other factors independently related to GS included advanced age (HR: 1.033, P < 0.001), male gender (HR: 1.835, P < 0.001), and the absence of diabetes (HR: 0.507, P < 0.001; Table 4).
Table 4
Factors independently correlated with the severity of coronary arterial atherosclerosis as detected by GS: multivariate logistic regression analysis
Variables
B
SE
Wald
P
HR
95% CI
Lower limit
Upper limit
Age
0.032
0.006
27.046
 < 0.001
1.033
1.020
1.045
Sex (male vs female)
0.607
0.173
12.363
 < 0.001
1.835
1.309
2.575
Diabetes mellitus (No vs Yes)
− 0.680
0.163
17.508
 < 0.001
0.507
0.368
0.696
Smoking
 Never smoker vs  current drinking
− 0.178
0.152
2.501
0.079
0.837
0.216
1.255
 Former smoker vs current drinking
− 0.237
0.171
3.390
0.059
0.790
0.310
1.098
Statins
− 0.470
0.245
3.666
0.056
0.625
0.386
1.011
NLR group
 1st tertile vs 3rd tertile
− 0.640
0.174
13.526
 < 0.001
0.527
0.375
0.742
 2nd tertile vs 3rd tertile
− 0.747
0.334
4.993
0.025
0.474
0.246
0.912
CI, confidence interval; HR, hazard ratio

Predictors of clinical outcomes

Overall, 65 patients experienced MACEs during follow-up, including 23 (35.38%) cases of cardiac mortality, 6 (9.23%) cases of nonfatal MI, 2 (3.08%) cases of ST, 33 (50.77%) cases of revascularization, and three (4.62%) cases of nonfatal stroke. The NLR was not correlated with MACEs either as a continuous variable or according to tertiles (both P > 0.05). Kaplan–Meier analysis did not show a significant difference in the event-free survival rate among the NLR tertiles (P < 0.775, Fig. 2). The results of univariable Cox regression analysis showed that age, systolic blood pressure, diastolic blood pressure, red blood cell count, left main coronary stenosis, stenosis of the right coronary artery, and high GS were predictors of MACEs (Table 5, all P < 0.05). Kaplan–Meier analysis also demonstrated that the risks of MACEs differed significantly different among the groups of different GS tertiles (P < 0.001). Multivariate Cox-regression analysis showed that age (HR: 1.049, 95% confidence interval [CI]: 1.024–1.075, P < 0.001), systolic blood pressure (HR: 1.029, 95% CI: 1.009–1.049, P = 0.005), and tertile of GS (3rd tertile vs. 1st tertile, HR: 3.216, 95% CI: 1.458–7.093, P = 0.004) were independent risk factors for MACEs.
Table 5
Predictors of the occurrence of MACEs in patients with new-onset ACS: results of univariate and multivariate Cox-regression analysesss
Variables
Univariate
Multivariate
HR
95% CI
P
HR
95% CI
P
Sex (Male/Female)
1.275
0.694–2.342
0.433
   
Age
1.051
1.029–1.073
 < 0.001
1.049
1.024–1.075
 < 0.001
Hypertension
0.918
0.562–1.499
0.731
   
Diabetes mellitus
1.175
0.676–2.044
0.568
   
Smoking
 Former smoker vs never smoker
1.177
0.161–8.616
0.872
   
 Current smoker vs never smoker
0.842
0.516–1.374
0.490
   
Alcohol drinking
 Former smoker vs never drinking
1.061
0.526–2.139
0.868
   
 Current smoker vs never drinking
1.390
0.797–2.423
0.246
   
Family history of CAD
0.876
0.529–1.450
0.605
   
SBP (mmHg)
1.029
1.016–1.042
 < 0.001
1.029
1.009–1.049
0.005
DBP (mmHg)
1.040
1.019–1.059
 < 0.001
1.007
0.978–1.038
0.626
Heart rate
1.008
0.992–1.024
0.319
   
BMI
0.965
0.928–1.003
0.072
   
HDL-C (mmol/l)
2.371
0.909–6.183
0.078
   
LDL-C (mmol/l)
1.238
0.913–1.680
0.169
   
TC (mmol/l)
1.132
0.905–1.416
0.278
   
TG (mmol/l)
0.956
0.813–1.123
0.583
   
ApoA1 (g/L)
1.170
0.662–2.067
0.589
   
ApoB (g/L)
1.118
0.574–2.181
0.742
   
Lp(a) (g/L)
0.999
0.997–1.001
0.150
   
Creatinine (mmol/L)
1.001
0.994–1.006
0.995
   
BUN (mmol/l)
0.978
0.881–1.086
0.675
   
Uric acid (μmol/L)
1.001
0.997–1.003
0.980
   
NLR group
 2nd tertile vs 1st tertile
1.155
0.643–2.075
0.629
   
 3rd tertile vs 1st tertile
0.940
0.509–1.734
0.843
   
Monocyte count
0.923
0.427–1.996
0.839
   
PLR
1.001
0.999–1.002
0.080
   
RBC
1.534
1.015–2.318
0.042
1.452
0.991–1.038
0.056
HGB
1.002
0.993–1.012
0.660
   
PLT
1.001
0.999–1.002
0.550
   
MPV
1.001
0.847–1.180
0.997
   
PDW
0.946
0.882–1.016
0.126
   
PCT
1.654
0.177–15.465
0.659
   
WBC
0.979
0.913–1.049
0.540
   
Clinical diagnosis
 NSTEMI
1.062
0.386–2.9222
0.907
   
 STEMI
0.862
0.3692.012
0.731
   
UPLMT
2.446
1.301–4.599
0.006
1.466
0.763–2.816
0.251
LAD
2.155
0.783–5.929
0.137
   
LCX
1.430
0.836–2.445
0.191
   
RCA
2.186
1.080–4.423
0.030
1.242
0.598–2.579
0.561
Aspirin
1.085
0.495–2.377
0.838
   
Statins
1.230
0.562–2.695
0.605
   
β-Blockers
0.756
0.237–2.410
0.637
   
ACEI/ARB
0.813
0.199–3.323
0.773
   
CCB
0.866
0.413–1.815
0.703
   
PCI
0.614
0.280–1.345
0.223
   
Gensini group
 2nd tertile vs 1st tertile
2.631
1.159–5.973
0.021
1.989
0.861–4.596
0.107
 3rd tertile vs 1st tertile
5.076
2.363–10.900
 < 0.001
3.216
1.458–7.093
0.004

Discussion

The results of this retrospective cohort study showed that, although a higher NLR at baseline was independently associated with the severity of coronary lesions in new-onset ACS patients as evidenced by GS, the NLR was not a predictor of adverse clinical outcome during follow-up. We found that advanced age, elevated systolic BP, and higher GS are potential independent predictors of poor outcomes. Taken together, our results do not support incorporation of baseline NLR as a prognostic factor for new-onset ACS patients.
The key pathophysiologic processes for ACS include the rupture of a vulnerable plaque and subsequent formation of thrombosis [25, 26], and the role of inflammation in these processes has not only been confirmed by pathological studies, but also shown in some optical coherence tomography-based studies [6, 27]. Therefore, it has been proposed that the NLR, a novel but easily obtained marker of inflammation, may be a prognostic factor for ACS patients. Indeed, some previous studies suggested a prognostic role for the NLR in CAD patients. In a recent study with 636 STEMI patients, the NLR was significantly associated with in-hospital mortality [28]. Moreover, a post-hoc analysis showed that the NLR is associated with increased long-term mortality in patients with acute myocardial infarction (AMI) complicated by left main- and/or three-vessel disease [15]. However, in our retrospective cohort study, we did not find a significant association between a high NLR and poor prognosis in these patients, despite the relatively longer follow-up duration in our study compared with previous studies. The mechanisms have yet to be fully determined. Previous studies showed that the NLR changes dramatically, with the maximal level seen during the occurrence of inflammatory-related events [29]. Because neutrophils have a short life span and faster turnover, it is better to observe neutrophils in a dynamic manner rather than in a single measurement. Moreover, our study had a longer follow-up duration than previous ones, which may indicate that the potential prognostic role of the NLR in ACS is only acute. The relationships of NLR with ACS, overall mortality, and cancer survival have generally been thought to be driven by chronic inflammation [1, 2]. However, patients with a previous diagnosis of CAD were excluded in our study, and whether the NLR is associated with new-onset ACS has not been well established and remains incompletely understood. To the best of our knowledge, the potential link between NLR and new onset ACS has not been reported.
Another explanation is that the potential prognostic role of the NLR in ACS is confounded by factors related to the severity of coronary lesions, such as the GS. Therefore, the prognostic efficacy of the NLR is limited in a model that incorporates factors reflecting the severity of coronary lesions. Our results indicated that the NLR is significantly correlated with coronary lesion severity as evidenced by the GS. The results of our present study confirm the previous concept that inflammation correlates with the degree of coronary stenosis in CAD patients. Pathophysiologically, myocardial ischemia can induce an immediate rise in the plasma NLR, the magnitude of which is proportional to the severity of ischemia, although the neutrophil half-life is short [30]. Subsequently, a state of stress and inflammation, as seen in ACS patients, could result in increased levels of inflammatory markers in the blood circulation, accompanied by increased blood cortisol levels. An increase in cortisol has been shown to induce apoptosis, which in turn leads to lymphopenia and even inversion of the CD4 + /CD8 + T lymphocyte ratio [31]. Therefore, an elevated NLR represents an exaggerated inflammatory response that may reflect coronary atherosclerosis progression [1618], and to some extent, may predict the acute prognosis in these patients [15, 3234]. On the other hand, medications such as statins are well known to have anti-inflammatory actions [35], and the common use of statins during the post-acute phase of ACS may also reduce the prognostic efficacy of the NLR for long-term outcomes in ACS patients. Xinjiang is characterized by the integration of diverse ethnic cultures, but people in Xinjiang generally do not have a deep understanding of cardiovascular disease. Accordingly, a low treatment rate and poor adherence are common problems of hypertension management in this area. Therefore, it appears that although approximately 50% of the patients had hypertension, only 3–15% of patients were receiving treatment with antihypertensive agents. We are working hard to actively promote popularization of the science of cardiovascular diseases in different forms and languages in this region.

Study limitations

First, as a retrospective observational single-center study with a small sample size, our study may be confounded by recall bias. Our results should be validated in prospective studies. Second, our study included consecutive patients with an initial diagnosis of ACS, and the diagnosis of the patients varied. Third, the NLR was only measured once at admission, and whether changes in the NLR during hospitalization or the NLR at discharge have an impact on the prognosis of these patients remains unknown. Finally, as the study was conducted over 8 years, PCI techniques and medical therapies likely evolved and changed with increasing evidence, which is likely to impact the outcome.

Conclusions

The NLR may be associated with coronary lesion severity at baseline but is not associated with adverse outcomes in patients with new-onset ACS.

Acknowledgements

Thanks to everyone for supporting our final study.
The study protocol was approved by the ethics committee of the Xinjiang Medical University Affiliated Hospital of Traditional Chinese Medicine. Because of the retrospective design of the study, the need to obtain informed consent.
From eligible patients was waived by the ethics committee.
Not applicable.

Competing interests

The authors declare that they have no conflict of interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Ridker PM, Everett Brendan M, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.CrossRef Ridker PM, Everett Brendan M, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.CrossRef
2.
Zurück zum Zitat Goldfine Allison B, Shoelson Steven E. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017;127:83–93.CrossRef Goldfine Allison B, Shoelson Steven E. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017;127:83–93.CrossRef
3.
Zurück zum Zitat Choi D-H, Kobayashi Y, Nishi T, et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long-term major adverse cardiovascular events after percutaneous coronary intervention. Angiology. 2019;70:345–51.CrossRef Choi D-H, Kobayashi Y, Nishi T, et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long-term major adverse cardiovascular events after percutaneous coronary intervention. Angiology. 2019;70:345–51.CrossRef
4.
Zurück zum Zitat Everett Brendan M, Pradhan Aruna D, Solomon Daniel H, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(199–207):e15. Everett Brendan M, Pradhan Aruna D, Solomon Daniel H, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(199–207):e15.
5.
Zurück zum Zitat Libby P, Ridker PM, Hansson GK. In-flammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–38.CrossRef Libby P, Ridker PM, Hansson GK. In-flammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–38.CrossRef
6.
Zurück zum Zitat Jun W, LiJun LX, et al. Mean platelet volume and coronary plaque vulnerability: an optical coherence tomography study in patients with non-ST-elevation acute coronary syndrome. BMC Cardiovasc Disord. 2019;19:128.CrossRef Jun W, LiJun LX, et al. Mean platelet volume and coronary plaque vulnerability: an optical coherence tomography study in patients with non-ST-elevation acute coronary syndrome. BMC Cardiovasc Disord. 2019;19:128.CrossRef
7.
Zurück zum Zitat Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904.CrossRef Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904.CrossRef
8.
Zurück zum Zitat Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA.2003; 290: 891–897. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA.2003; 290: 891–897.
9.
Zurück zum Zitat Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.CrossRef Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.CrossRef
10.
Zurück zum Zitat Rajagopal V, Gurm HS, Bhatt DL, et al. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol. 2004;94:190–2.CrossRef Rajagopal V, Gurm HS, Bhatt DL, et al. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol. 2004;94:190–2.CrossRef
11.
Zurück zum Zitat Barron H, Harr S, Radford M, et al. The association between white blood cell count and acute myocardial infarction mortality in patients > or = 65 years of age: Findings from the cooperative cardiovascular project. J Am Coll Cardiol. 2001;38(6):1654–61.CrossRef Barron H, Harr S, Radford M, et al. The association between white blood cell count and acute myocardial infarction mortality in patients > or = 65 years of age: Findings from the cooperative cardiovascular project. J Am Coll Cardiol. 2001;38(6):1654–61.CrossRef
12.
Zurück zum Zitat Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86:449–51.CrossRef Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86:449–51.CrossRef
13.
Zurück zum Zitat Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis. Sci Rep. 2016;6:38551.CrossRef Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis. Sci Rep. 2016;6:38551.CrossRef
14.
Zurück zum Zitat Huankun S, Jiaqun Q, Yangpei P, et al. The neutrophil-lymphocyte ratio: a promising predictor of mortality in coronary care unit patients - a cohort study. Int Immunopharmacol. 2019;74:105692.CrossRef Huankun S, Jiaqun Q, Yangpei P, et al. The neutrophil-lymphocyte ratio: a promising predictor of mortality in coronary care unit patients - a cohort study. Int Immunopharmacol. 2019;74:105692.CrossRef
15.
Zurück zum Zitat Na Xu, Xiao-Fang T, Yi Y, et al. Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction. Catheter Cardiovasc Interv. 2018;91:551–7.CrossRef Na Xu, Xiao-Fang T, Yi Y, et al. Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction. Catheter Cardiovasc Interv. 2018;91:551–7.CrossRef
16.
Zurück zum Zitat Kaya A, Kurt M, Tanboga IH, et al. Relation of neutrophil to lymphocyte ratio with the presence and severity of stable coronary artery disease. Clin Appl Thromb Hemost. 2014;20:473–7.CrossRef Kaya A, Kurt M, Tanboga IH, et al. Relation of neutrophil to lymphocyte ratio with the presence and severity of stable coronary artery disease. Clin Appl Thromb Hemost. 2014;20:473–7.CrossRef
17.
Zurück zum Zitat Kurtul S, Sarli B, Baktir AO, et al. Neutrophil to lymphocyte ratio predicts SYNTAX score in patients with non-ST segment elevation myocardial infarction. Int Heart J. 2015;56:18–21.CrossRef Kurtul S, Sarli B, Baktir AO, et al. Neutrophil to lymphocyte ratio predicts SYNTAX score in patients with non-ST segment elevation myocardial infarction. Int Heart J. 2015;56:18–21.CrossRef
18.
Zurück zum Zitat Kaya H, Ertaş F, Soydinç MS. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost. 2014;20:221.CrossRef Kaya H, Ertaş F, Soydinç MS. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost. 2014;20:221.CrossRef
19.
Zurück zum Zitat Mendis S, Thygesen K, Koulasmaa K, et a1. Wodd Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol, 2011, 40(1): 139·146 Mendis S, Thygesen K, Koulasmaa K, et a1. Wodd Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol, 2011, 40(1): 139·146
20.
Zurück zum Zitat Wang J, Zhang L, Wang F, Liu L, Wang H. China National Survey of Chronic Kidney Disease Working Group. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens.2014;27:1355–61. Wang J, Zhang L, Wang F, Liu L, Wang H. China National Survey of Chronic Kidney Disease Working Group. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens.2014;27:1355–61.
21.
Zurück zum Zitat Olafsdottir E, Andersson DK, Dedorsson I, Stefey. Am J Hypertens.2014 fretinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmol. 2014;92(2):133–7. Olafsdottir E, Andersson DK, Dedorsson I, Stefey. Am J Hypertens.2014 fretinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmol. 2014;92(2):133–7.
22.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, et al; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470. Levey AS, Bosch JP, Lewis JB, et al; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470.
23.
Zurück zum Zitat Alpert JS. Universal definition of myocardial infarction. Eur Heart J. 2008;29(9):1209. Alpert JS. Universal definition of myocardial infarction. Eur Heart J. 2008;29(9):1209.
24.
Zurück zum Zitat Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.CrossRef Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.CrossRef
25.
Zurück zum Zitat Sinning C, Zengin E, Waldeyer C, et al. SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. Clin Res Cardiol. 2016;105:901–11.CrossRef Sinning C, Zengin E, Waldeyer C, et al. SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. Clin Res Cardiol. 2016;105:901–11.CrossRef
26.
Zurück zum Zitat Lozano R, Naghavi MK, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRef Lozano R, Naghavi MK, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRef
27.
Zurück zum Zitat Potenza MA, Nacci C, De SMA, et al. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacol Res. 2017;120:226–41.CrossRef Potenza MA, Nacci C, De SMA, et al. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacol Res. 2017;120:226–41.CrossRef
28.
Zurück zum Zitat Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003;108:282.CrossRef Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003;108:282.CrossRef
29.
Zurück zum Zitat Wei P, Deliang Z, Canxiu Z, et al. Application of neutrophil/lymphocyte ratio in predicting coronary blood flow and mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. J Cardiol. 2015;66:9–14.CrossRef Wei P, Deliang Z, Canxiu Z, et al. Application of neutrophil/lymphocyte ratio in predicting coronary blood flow and mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. J Cardiol. 2015;66:9–14.CrossRef
30.
Zurück zum Zitat Kim S, Eliot M, Koestler Devin C, et al. Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant. JAMA Cardiol. 2018;3:455–62.CrossRef Kim S, Eliot M, Koestler Devin C, et al. Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant. JAMA Cardiol. 2018;3:455–62.CrossRef
31.
Zurück zum Zitat Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol 2004;25:315e22. Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol 2004;25:315e22.
32.
Zurück zum Zitat Fiarresga AJ, Ferreira RC, Feliciano J, et al. Prognostic value of neutrophil response in the era of acute myocardial infarction mechanical reperfusion. Rev Port Cardiol. 2004;23:1387–96.PubMed Fiarresga AJ, Ferreira RC, Feliciano J, et al. Prognostic value of neutrophil response in the era of acute myocardial infarction mechanical reperfusion. Rev Port Cardiol. 2004;23:1387–96.PubMed
33.
Zurück zum Zitat Vakili H, Shirazi M, Charkhkar M, et al. Correlation of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest. 2017;47:322–7.CrossRef Vakili H, Shirazi M, Charkhkar M, et al. Correlation of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest. 2017;47:322–7.CrossRef
34.
Zurück zum Zitat Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with STelevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110:621–7.CrossRef Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with STelevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110:621–7.CrossRef
35.
Zurück zum Zitat Habib H, Sadegh PSM, Najmaldin S. Evaluation of complete blood count parameters in cardiovascular diseases: An early indicator of prognosis? Exp Mol Pathol. 2019;110:104267.CrossRef Habib H, Sadegh PSM, Najmaldin S. Evaluation of complete blood count parameters in cardiovascular diseases: An early indicator of prognosis? Exp Mol Pathol. 2019;110:104267.CrossRef
36.
Zurück zum Zitat Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64:2207–17.CrossRef Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64:2207–17.CrossRef
Metadaten
Titel
Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study
verfasst von
Yi Yang
Yanan Xu
Jun Wang
Xueqin Zhai
Haibing Jiang
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2020
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01773-x

Weitere Artikel der Ausgabe 1/2020

BMC Cardiovascular Disorders 1/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.